Establishment Labs (ESTA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
16 Aug, 2026Executive summary
Q2 2026 revenue reached $67.5 million, up 31.7% year-over-year, with adjusted EBITDA of $3.7 million, marking a turnaround from a loss last year.
Revenue for the first half of 2026 increased 37.5% year-over-year to $127.4 million, driven by strong U.S. and international sales.
U.S. revenue surged 140.9% to $24.7 million in Q2, now 36.6% of total revenue, fueled by Motiva adoption and Minimally Invasive platform growth.
Gross margin improved to 70.6% in Q2 2026, up from 68.8% in Q2 2025, driven by higher-margin markets and favorable product mix.
Cash and equivalents ended at $71.2 million as of June 30, 2026, up $16.5 million year-over-year.
Financial highlights
Gross profit for Q2 2026 was $47.7 million (70.6% margin), up from $35.3 million (68.8% margin) in Q2 2025.
Operating expenses for Q2 2026 totaled $52.0 million, with strong operating leverage and $2.2 million in one-time charges.
Adjusted EBITDA improved by $12.2 million year-over-year, turning from a loss to a $3.7 million gain in Q2 2026.
Net loss narrowed to $11.7 million in Q2 2026 from $16.6 million in Q2 2025; net loss per share was $(0.39).
Interest expense increased to $7.0 million in Q2 2026 due to higher debt levels.
Outlook and guidance
Full-year revenue guidance raised to $269–$271 million, with U.S. as primary growth driver and OUS business stable.
Minimally Invasive platform expected to be about 15% of 2026 revenue.
Free cash flow positive expected in H2 2026 and for full-year 2027.
2027 revenue growth projected around 25%.
Management expects strong growth in the second half of 2026 and into 2027, with a focus on achieving free cash flow positivity.
Latest events from Establishment Labs
- All proposals passed with majority approval and no shareholder questions were raised.ESTA
AGM 2026 - Q1 revenue up 45% year-over-year, gross margin at 70.7%, and 2026 guidance raised.ESTA
Q1 2026 - Director compensation figures were corrected, and additional equity awards disclosed for consulting roles.ESTA
Proxy filing - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong governance focus.ESTA
Proxy filing - Vote on directors, executive pay, and auditor ratification at the May 2026 annual meeting.ESTA
Proxy filing - Rapid U.S. growth, premium pricing, and innovation set the stage for market dominance and expansion.ESTA
TD Cowen 46th Annual Health Care Conference - Q4 revenue up 45%, gross margin at 70.5%, and 2026 revenue growth guided above 25%.ESTA
Q4 2025 - Q2 revenue rose 18.7% sequentially; FDA approval for Motiva Implants expected soon.ESTA
Q2 2024 - 2025 guidance targets $205–$210M revenue, EBITDA positive, and rapid US-driven growth.ESTA
Investor Day 2025